Literatur
- 1
Anderson P.
Cost
of failing to achieve targets for blood pressure control in Europe.
J
Hypertension.
2001;
19
S75
- 2
Berlowitz D R, Ash A S, Hickey E C.
Inadequate management of blood pressure
in a hypertensive population.
N Engl J Med.
1998;
339
1957-1963
- 3
Hosie J, Wiklund I.
Managing hypertension in general
practice: can we do better?.
J Hum Hypertens.
1995;
9
S15-18
- 4
Hyman D J, Pavlik V N.
Self-reported
hypertension treatment practices among primary care physicians:
blood pressure thresholds, drug choices, and the role of guidelines
and evidence-based medicine.
Arch Intern Med.
2000;
160
2281-2286
- 5
Lloyd-Jones D M, Evans J C, Larson M G, Levy D.
Treatment
and control of hypertension in the community.
Hypertension.
2002;
40
640-646
- 6
Mann J, Julius S.
The Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) trial of cardiovascular events
in hypertension. Rationale and design.
Blood Pressure.
1998;
7
176-183
- 7
The ALLHAT Officers .
Major
outcomes in moderately hypercholesteremic, hypertensive patients
randomised to ACE I or CCB vs diuretic.
JAMA.
2002;
288
2981-2987
- 8
Leonetti G, Cuspidi C, Facchini M, Stramba-Badiale M.
Is systolic
pressure a better target for antihypertensive treatment than diastolic pressure?.
J
Hypertens .
2000;
18(3)
(Suppl)
S13-20
- 9
Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J,
Rahn K H, Wedel H, Westerling S.
Effects
of intensive blood-pressure lowering and low-dose aspirin in patients
with hypertension: principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. HOT STudy Group.
Lancet.
1998;
351 (9118)
1755-62
Prof. Dr. Roland E. Schmieder
Medizinische Klinik IV
Krankenhausstraße 12
91054 Erlangen
Phone: 49/9131/8539209
Fax: 49/9131/8539002
Email: roland.schmieder@rzmail.uni-erlangen.de
